Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide (NNC90-1170) Dose-Response in Type 2 Diabetes
NCT01509755Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2000
- Primary completion
- Oct 2001
- Modality
- Peptides
- Countries
- 4
01
Overview
A Phase 2 trial of liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Oct 2000; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01509755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01509755.